Trending...
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
- Cal State LA secures funding for two artificial intelligence projects from CSU
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 10, 2022, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 28,250 shares of common stock and 14,100 restricted stock units ("RSUs") to eight new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $24.93 per share, Mirum's closing trading price on August 10, 2022, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum's approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Please view the warnings and precautions available in the Prescribing information or, for more information, visit LIVMARLI.com.
More on The Californer
Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum's second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
More on The Californer
Learn more about Mirum by visiting www.mirumpharma.com. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
Contacts
Investor Contacts:
Ian Clements, Ph.D.
ir@mirumpharma.com
Sam Martin
Argot Partners
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Each stock option has an exercise price per share equal to $24.93 per share, Mirum's closing trading price on August 10, 2022, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum's approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Please view the warnings and precautions available in the Prescribing information or, for more information, visit LIVMARLI.com.
More on The Californer
- Fastest Growing Staffings Firms
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Rachel Farris, CPA Featured on The AJ Brown Show to Discuss Act 60 Tax Incentives
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum's second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
More on The Californer
- Jade & Zelda Launch Virtually Human: A Groundbreaking Podcast Hosted by AI-Powered Virtual Humans
- Dr. Satyam Priyadarshy Joins Indemnify AI to Enrich AI Risk Financial Quantification
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Fact: Trump lied — again. California gas prices remain lower than a week ago, month ago, and a year ago
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
Learn more about Mirum by visiting www.mirumpharma.com. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
Contacts
Investor Contacts:
Ian Clements, Ph.D.
ir@mirumpharma.com
Sam Martin
Argot Partners
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Filed Under: Business
0 Comments
Latest on The Californer
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Revolutionary conversational AI transforms customer engagement with professional virtual receptionist answering service tailored for small busines
- New AI platform helps small businesses deliver always-available, professional customer service without added staff or complexity
- VoiceGenie AI empowers small businesses with 24/7, brand-driven customer engagement through an AI-powered virtual front desk receptionist
- California: Governor Newsom signs tribal-state gaming compact 7.14.25
- VoiceGenie AI empowers small businesses with human-like call answering and customer engagement—bridging the gap between automation and live
- New 24/7 AI solution transforms customer engagement and efficiency for small businesses seeking live virtual receptionist services
- Next-generation virtual receptionist service leverages AI to ensure every customer call and text is answered, enhancing efficiency and engagem
- Next-Gen AI Receptionist Elevates Customer Communication, Boosts Efficiency for Small Businesses
- California: Governor Newsom signs legislation 7.14.25
- New AI-Powered Platform from Kell Web Solutions Delivers 24/7 Professional, Automated Call Handling and Appointment Scheduling
- Kell Web Solutions Launches Next-Gen VoiceGenie AI Call Answering Service for Businesses
- 24/7 Conversational AI Platform Raises the Standard for Small Business Customer Engagement
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- QuickLogic Announces the Passing of Board Director Christine Russell
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- IEI USA Launches SHIELD Rugged Stainless Steel Panel PCs for Hygiene-Critical Industries
- In historic first, California powered by two-thirds clean energy – becoming largest economy in the world to achieve milestone
- North Island Credit Union Foundation Provides $5,000 in Teacher Grants To Benefit Educators & Students
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison